Table 1 Description of HRT Trials.
Study | Length months | Type of Oestrogen | Progestin+ Addition of calcium* | Study Population | Outcome measure | Age (SD/range) |
|---|---|---|---|---|---|---|
Alexandersen 1999 [12] | 22 | 50-ug transdermal estradiol | +* | Healthy postmenopausal women with low BMD | BMD | 65 (2.2) |
Delmas 2000 [5] | 24 | Oral 1 mg estradiol | +* | Healthy >1 year postmenopausal women with normal BMD. | BMD | 58 (5) |
Gallagher 2001 [14] | 36 | Oral 0.625 mg conjugated estrogens | +* | Elderly women with normal bone density | BMD | 72(± 4) |
Cauley 2001 [4] | 49 | Oral 0.625 conjugated estrogen | + | Women with established coronary disease >5 years post menopause | MI or CHD | 67 |
Herrington 2000 [6] | 38 | Oral 0.625 conjugated estrogen | + | Women with coronary arterial disease (CAD) | CAD Progression | 66 (7.0) |
Ishida 2001 [15] | 12 | Oral 0.625 conjugated estrogen. | + | Women with established osteoporosis. | BMD | 70 (7.6) |
Lindsay 1990 [13] | 24 | Oral 0.625 mg conjugated estrogen | +* | Postmenopausal women with 1+ vertebral fracture & low BMD | BMD | 48 (1.0) |
Lufkin 1992 [1] | 12 | Transdermal 0.1 mg 17β-estradiol | + | Postmenopausal white women with documented osteoporosis | BMD | 64.8 (54.9 to 71.3) |
Mosekilde 2000 [7] | 60 | Oral 1 mg or 2 mg estradiol | + | Healthy women 3–24 months post menopause | Fractures | 50 (2.8) |
PEPI 1996 [8] | 36 | Oral 0.625 mg conjugated estrogen | + | Healthy women 1–10 years post menopause normal BMD | BMD | 56 (0.3) |
Ravn 1999 [9] | 48 | Oral 0.625 conjugated estrogen or 2 mg estradiol | + | Healthy 6+ months postmenopausal women under 60 years | BMD | 55 |
Recker 1999 [10] | 42 | 0.3 mg conjugated estrogen | +* | Healthy women average BMD t-score-3.5 at femur | BMD | 73 (5.0) |
Wimalawansa 1998 [11] | 48 | Oral 0.625 conjugated estrogen | +* | Women with established osteoporosis (1+vertebral fracture) | BMD | 65 (0.9) |